Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL

References

• Burger JA. Treatment of chronic lymphocytic leukemia. N Engl J Med. 2020;383(5):460–473.
   PubMed Web of Science ®Google Scholar
• Thompson PA, Peterson CB, Strati P, et al. Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. Leukemia. 2018;32(11):2388–2398.
   PubMed Web of Science ®Google Scholar
• Del Giudice I, Raponi S, Della Starza I, et al. Minimal residual disease in chronic lymphocytic leukemia: a new goal? Front Oncol. 2019;9:689.
   PubMed Web of Science ®Google Scholar
• Molica S, Giannarelli D, Montserrat E. Minimal residual disease and survival outcomes in patients with chronic lymphocytic leukemia: a systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2019;19(7):423–430.
   PubMed Web of Science ®Google Scholar
• Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German chronic lymphocytic leukemia study group. J Clin Oncol. 2012;30(26):3209–3216.
   PubMed Web of Science ®Google Scholar
• Bottcher S, Ritgen M, Fischer K, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2012;30(9):980–988.
   PubMed Web of Science ®Google Scholar
• Strati P, Keating MJ, O'Brien SM, et al. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood. 2014;123(24):3727–3732.
   PubMed Web of Science ®Google Scholar
• Kovacs G, Robrecht S, Fink AM, et al. Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: comprehensive analysis of two phase III studies of the German CLL study group. J Clin Oncol. 2016;34(31):3758–3765.
   PubMed Web of Science ®Google Scholar
• Dimier N, Delmar P, Ward C, et al. A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL. Blood. 2018;131(9):955–962.
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164–1174.
   PubMed Web of Science ®Google Scholar
• Eichhorst B, Fink AM, Bahlo J, German CLL Study Group (GCLLSG), et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17(7):928–942.
   PubMed Web of Science ®Google Scholar
• Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101–1110.
   PubMed Web of Science ®Google Scholar
• Bosch F, Cantin G, Cortelezzi A, et al. Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study. Leukemia. 2020;34(2):441–450.
   PubMed Web of Science ®Google Scholar
• Robak T, Dmoszynska A, Solal-Céligny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010;28(10):1756–1765.
   PubMed Web of Science ®Google Scholar
• Burger JA, O'Brien S. Evolution of CLL treatment - from chemoimmunotherapy to targeted and individualized therapy. Nat Rev Clin Oncol. 2018;15(8):510–527.
   PubMed Web of Science ®Google Scholar
• Eichhorst B, Robak T, Montserrat E, ESMO Guidelines Committee. Electronic address: [email protected], et al. Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(1):23–33.
   PubMed Web of Science ®Google Scholar
• FDA. Calquence. Highlights of prescribing information; 2021 [cited 2021 Jun 17]. Available from: https://www.azpicentral.com/calquence/calquence.pdf#page=1.
   Google Scholar
• FDA. Copiktra. Highlights of prescribing information; [cited 2021 Jun 17]. Available from: https://copiktra.com/pdf/verastem/COPIKTRA-PI-072019.pdf.
   Google Scholar
• FDA. Imbruvica. Highlights of prescribing information; 2021 [cited 2021 Jun 17]. Available from: https://imbruvica.com/files/prescribing-information.pdf.
   Google Scholar
• FDA. Zydelig. Highlights of prescribing information; 2021 [cited 2021 Jun 17]. Available from: https://www.gilead.com/∼/media/Files/pdfs/medicines/oncology/zydelig/zydelig_pi.pdf.
   Google Scholar
• Hallek M, Cheson BD, Catovsky D, International Workshop on Chronic Lymphocytic Leukemia, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the National Cancer Institute-Working group 1996 guidelines. Blood. 2008;111(12):5446–5456.
   PubMed Web of Science ®Google Scholar
• Munir T, Rawstron A, Brock K, et al. Ibrutinib plus venetoclax in relapsed/refractory CLL: results of the bloodwise TAP clarity study. Br J Haematol. 2019;185, 25 (conference paper).
   PubMed Web of Science ®Google Scholar
• Byrd JC, Hillmen P, O’Brien S, et al. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood. 2019;133(19):2031–2042.
   PubMed Web of Science ®Google Scholar
• Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–2437.
   PubMed Web of Science ®Google Scholar
• Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517–2528.
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib–rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381(5):432–443.
   PubMed Web of Science ®Google Scholar
• Lampson BL, Tyekucheva S, Crombie JL, et al. Preliminary safety and efficacy results from a phase 2 study of acalabrutinib, venetoclax and obinutuzumab in patients with previously untreated chronic lymphocytic leukemia (CLL). Blood. 2019;134(Supplement_1):e470–e479.
   Google Scholar
• Davids MS, Fisher DC, Tyekucheva S, et al. A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients. Leukemia. 2021;35(4):1064–1072.
   PubMed Web of Science ®Google Scholar
• Sharman JP, Coutre SE, Furman RR, et al. Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia. J Clin Oncol. 2019;37(16):1391–1402.
   PubMed Web of Science ®Google Scholar
• Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(1):43–56.
   PubMed Web of Science ®Google Scholar
• Molica S. The evolving role of time-limited targeted therapy in chronic lymphocytic leukemia. Expert Rev Anticancer Ther. 2020;20(12):1015–1019.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107–1120.
   PubMed Web of Science ®Google Scholar
• Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225–2236.
   PubMed Web of Science ®Google Scholar
• Al-Sawaf O, Zhang C, Robrecht S, et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 4-year follow-up analysis of the randomized CLL14 study. Abstract Book for the 26th Congress of the European Hematology Association Virtual Edition, 2021, in HemaSphere: June 2021 - Volume 5; 2021 Jun 9–17.
   Google Scholar
• Kater AP, Kipps T, Eichhorst B, et al. Five-year analysis of Murano study demonstrates enduring undetectable minimal residual disease (uMRD) in a subset of relapsed/refractory chronic lymphocytic leukemia (R/R CLL) patients (pts) following fixed-duration venetoclax-rituximab (VenR) therapy (tx). American Society of Hematology Annual Meeting & Exposition (virtual), Blood (2020) 136 (Supplement 1): 19–21.
   Google Scholar
• Kater AP, Seymour JF, Hillmen P, et al. Fixed duration of venetoclax-rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study. J Clin Oncol. 2019;37(4):269–277.
   PubMed Web of Science ®Google Scholar
• Kater AP, Kersting S, van Norden Y, HOVON CLL Study Group, et al. Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL. Blood Adv. 2018;2(24):3566–3571.
   PubMed Web of Science ®Google Scholar
• Fischer K, Al-Sawaf O, Fink AM, et al. Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood. 2017;129(19):2702–2705.
   PubMed Web of Science ®Google Scholar
• Ma S, Seymour JF, Brander DM, et al. Efficacy of venetoclax plus rituximab for relapsed CLL: five-year follow-up of continuous or limited-duration therapy. Blood. 2021;138(10):836–846.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Ma S, Brander DM, et al. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol. 2017;18(2):230–240.
   PubMed Web of Science ®Google Scholar
• Munn Z, Peters MDJ, Stern C, et al. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med Res Methodol. 2018;18(1):143.
   PubMed Web of Science ®Google Scholar
• Ahn IE, Farooqui MZH, Tian X, et al. Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study. Blood. 2018;131(21):2357–2366.
   PubMed Web of Science ®Google Scholar
• Wang XV, Hanson CA, Tschumper RC, et al. Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib. Blood. 2021;138(26):2810–2827.
   PubMed Web of Science ®Google Scholar
• Fraser G, Cramer P, Demirkan F, et al. Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia. 2019;33(4):969–980.
   PubMed Web of Science ®Google Scholar
• Al-Sawaf O, Zhang C, Tandon M, et al. Fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: follow-up of efficacy and safety results from the multicenter, open-label, randomized phase 3 CLL14 trial. Abstract Book for the 25th Congress of the European Hematology Association Virtual Edition, 2020, in HemaSphere: June 2020 - Volume 4; 2020 Jun 11–21.
   Google Scholar
• Al-Sawaf O, Zhang C, Tandon M, et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020;21(9):1188–1200.
   PubMed Web of Science ®Google Scholar
• Al-Sawaf O, Zhang C, Tandon M, CLL14 Study Investigators, et al. Fixed-duration venetoclax-obinutuzumab for previously untreated patients with chronic lymphocytic leukemia: Follow-up of efficacy and safety results from the multicenter, open-label, randomized, phase III CLL14 trial. J Clin Oncol. 2020;38(15_suppl):8027–8027.
   Web of Science ®Google Scholar
• Al-Sawaf O, Zhang C, Robrecht S, et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 4-year follow-up analysis of the randomized CLL14 study. Hematol Oncol. 2021;39(S2):201–203.
   Google Scholar
• Kater AP, Arslan O, Demikran F, et al. Efficacy of venetoclax in patients with relapsed/refractory chronic lymphocytic leukemia: primary endpoint analysis of the international phase 3b trial (VENICE I). Abstract Book for the 25th Congress of the European Hematology Association Virtual Edition, 2020, in HemaSphere: June 2020 - Volume 4; 2020 Jun 11–21.
   Google Scholar
• Byrd JC, Wierda WG, Davids MS, et al. Durability of response to venetoclax (VEN) in patients with CLL relapsed/refractory to ibrutinib and/or idelalisib. J Clin Oncol. 2018;36(15_suppl):7512–7512.
   Web of Science ®Google Scholar
• Jones JA, Mato AR, Wierda WG, et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19(1):65–75.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial. J Clin Oncol. 2018;36(19):1973–1980.
   PubMed Web of Science ®Google Scholar
• Kater AP, Wu JQ, Kipps T, et al. Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study. J Clin Oncol. 2020;38(34):4042–4054.
   PubMed Web of Science ®Google Scholar
• Munir T, Moreno C, Owen C, et al. First prospective data on minimal residual disease (MRD) outcomes after fixed-duration ibrutinib plus venetoclax (ibr + ven) versus chlorambucil plus obinutuzumab (clb + o) for first-line treatment of CLL in elderly or unfit patients: the glow study. Blood. 2021;138(Supplement 1):70–70.
   Google Scholar
• Abrisqueta P, Gonzalez Barca E, Ferra CM, et al. Preliminary results of ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC7 trials from the Spanish group of CLL (GELLC). Blood. 2019;134(Supplement_1):4296–4296.
   Google Scholar
• Burger JA, Sivina M, Jain N, et al. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood. 2019;133(10):1011–1019.
   PubMed Web of Science ®Google Scholar
• Sharman JP, Farber CM, Mahadevan D, et al. Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial. Br J Haematol. 2017;176(3):412–420.
   PubMed Web of Science ®Google Scholar
• Lipsky AH, Hill BT, Winter AM, et al. High rates of undetectable minimal residual disease remissions with time-limited bendamustine, rituximab, and venetoclax (BR-VR) in untreated chronic lymphocytic leukemia (CLL). Blood. 2021;138(Supplement 1):1555–1555.
   Google Scholar
• Wu JQ, Seymour JF, Eichhorst B, et al. Unfavorable genetics impact MRD response to venetoclax + rituximab retreatment in relapsed or refractory chronic lymphocytic leukemia (R/R CLL): phase 3 MURANO substudy. Hematol Oncol. 2021;39(S2):203–205.
   Google Scholar
• Jain N, Ferrajoli A, Yilmaz M, et al. Venetoclax, obinutuzumab and atezolizumab (PD-L1 checkpoint inhibitor) for first-line treatment for patients with chronic lymphocytic leukemia (CLL). Blood. 2021;138(Supplement 1):2626–2626.
   Google Scholar
• Staber PB, Jurczak W, Greil R, et al. Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor. Leuk Lymphoma. 2021;62(14):3440–3451.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Rawstron AC, Brock K, et al. Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: the CLARITY study. J Clin Oncol. 2019;37(30):2722–2729.
   PubMed Web of Science ®Google Scholar
• Wierda WG, Allan JN, Siddiqi T, et al. Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study. J Clin Oncol. 2021;39(34):3853–3865.
   PubMed Web of Science ®Google Scholar
• Niemann CU, Dubois J, Brieghel C, et al. Time-limited venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) who have undetectable MRD – primary analysis from the randomized phase II vision HO141 trial. Blood. 2021;138(Supplement 1):69–69.
   Google Scholar
• von Tresckow J, Cramer P, Bahlo J, et al. CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia. Leukemia. 2019;33(5):1161–1172.
   PubMed Web of Science ®Google Scholar
• Michallet AS, Letestu R, Le Garff-Tavernier M, et al. A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial. Blood. 2021;137(8):1019–1023.
   PubMed Web of Science ®Google Scholar
• Michallet AS, Dilhuydy MS, Subtil F, et al. Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2019;6(9):e470–e479.
   PubMed Web of Science ®Google Scholar
• Davids MS, Brander DM, Kim HT, Blood Cancer Research Partnership of the Leukemia & Lymphoma Society, et al. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2019;6(8):e419–e428.
   PubMed Web of Science ®Google Scholar
• Cramer P, Tresckow JV, Robrecht S, et al. Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial. Haematologica. 2021;106(2):543–554.
   PubMed Web of Science ®Google Scholar
• Davids M, Fisher D, Tyekucheva S, et al. A phase Ib/II study of duvelisib in combination with FCR (DFCR) for frontline therapy of younger CLL patients. Abstract Book for the 23rd Congress of the European Hematology Association Stockholm, Sweden, June 14-17, 2018 in HemaSphere: June 2018 - Volume 2, page 351.
   Google Scholar
• Coutre S, Choi M, Furman RR, et al. Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. Blood. 2018;131(15):1704–1711.
   PubMed Web of Science ®Google Scholar
• Sharman JP, Brander DM, Mato AR, et al. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial. Lancet Haematol. 2021;8(4):e254–e266.
   PubMed Web of Science ®Google Scholar
• Sharman JP, Brander DM, Mato AR, et al. Effect of adding ublituximab to ibrutinib on PFS, ORR, and MRD negativity in previously treated high-risk chronic lymphocytic leukemia: final results of the GENUINE phase III study. J Clin Oncol. 2020;38(15_suppl):8022–8022.
   Web of Science ®Google Scholar
• Levin M-D, Dubois J, Nasserinejad K, et al. MRD-guided or fixed 12 cycles of venetoclax consolidation after venetoclax plus obinutuzumab treatment in first-line FCR unfit patients with CLL: primary endpoint analysis of the HOVON 139/GIVE trial. HemaSphere. 2021;5(S2):29.
   Google Scholar
• Levin MD, Kersting S, Van Norden Y, et al. Obinutuzumab pre-induction abrogates high tumor lysis risk of venetoclax in treatment naive FCR-unfit patients with chronic lymphocytic leukemia: a planned interim analysis. Abstract Book for the 23rd Congress of the European Hematology Association Stockholm, Sweden, June 14-17, 2018 in HemaSphere: June 2018 - Volume 2: page 126.
   Google Scholar
• Cramer P, von Tresckow J, Bahlo J, et al. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19(9):1215–1228.
   PubMed Web of Science ®Google Scholar
• Wu J, Bolen C, Seymour JF, et al. Impact of major genomic alterations on outcome of relapsed/refractory chronic lymphocytic leukemia patients receiving venetoclax plus rituximab in the phase 3 MURANO study. Hematol Oncol. 2019;37(S2):106–108.
   Google Scholar
• Kater A, Owen C, Moreno C, et al. Fixed-duration ibrutinib and venetoclax (I + V) versus chlorambucil plus obinutuzumab (clb + O) for first-line (1L) chronic lymphocytic leukemia (CLL): primary analysis of the phase 3 GLOW study. Abstract Book for the 26th Congress of the European Hematology Association Virtual Edition, 2021, in HemaSphere: June 2021 - Volume 5 Jun 9–17.
   Google Scholar
• Ghia P, Allan JN, Siddiqi T, et al. Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): primary analysis of the FD cohort of the phase 2 captivate study. J Clin Oncol. 2021;39(15_suppl):7501–7501.
   Web of Science ®Google Scholar
• Tam CSL, Allan JN, Siddiqi T, et al. CAPTIVATE primary analysis of first-line treatment with fixed-duration ibrutinib plus venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL. Hematol Oncol. 2021;39(S2):66–68.
   PubMedGoogle Scholar
• Jain N, Keating M, Thompson P, et al. Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: a nonrandomized phase 2 trial. JAMA Oncol. 2021;7(8):1213–1219.
   PubMed Web of Science ®Google Scholar
• Davids MS, Lampson BL, Tyekucheva S, et al. Updated safety and efficacy results from a phase 2 study of acalabrutinib, venetoclax and obinutuzumab (AVO) for frontline treatment of chronic lymphocytic leukemia (CLL). Blood. 2020;136(Supplement 1):20–21.
   Google Scholar
• Davids MS, Lampson BL, Tyekucheva S, et al. Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. Lancet Oncol. 2021;22(10):1391–1402.
   PubMed Web of Science ®Google Scholar
• Baliakas P, Jeromin S, Iskas M, ERIC, the European Research Initiative on CLL, et al. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. Blood. 2019;133(11):1205–1216.
   PubMed Web of Science ®Google Scholar
• Wu JQ, Seymour JF, Eichhorst B, et al. Impact of unfavorable genetics on minimal residual disease (MRD) response to venetoclax + rituximab retreatment in relapsed or refractory chronic lymphocytic leukemia (R/R CLL): phase 3 MURANO substudy. HemaSphere. 2021;5(S2):265–266.
   Google Scholar
• Rogers KA, Huang Y, Ruppert AS, et al. Phase II study of combination obinutuzumab, ibrutinib, and venetoclax in treatment-naïve and relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020;38(31):3626–3637.
   PubMed Web of Science ®Google Scholar
• Jain N, Thompson PA, Burger JA, et al. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) for first-line treatment of IGHV-mutated CLL and without del(17p)/mutated TP53. Blood. 2019;134(Supplement_1):357–357.
   Google Scholar
• Jain N, Thompson P, Burger J, et al. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia. 2021;35(12):3421–3429.
   PubMed Web of Science ®Google Scholar
• Rawstron A, Webster N, Dalal S, et al. Kinetics of response in the peripheral blood predicts long-term responses to ibrutinib + venetoclax treatment for relapsed/refractory CLL in the Bloodwise TAP Clarity trial. Abstract Book for the 25th Congress of the European Hematology Association Virtual Edition, 2020, in HemaSphere: June 2020 - Volume 4; 2020 Jun 11–21.
   Google Scholar
• Davids MS, Brander DM, Tyekucheva S, et al. Longer term follow-up of a multicenter, phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, rituximab (iFCR) as initial therapy for younger patients with chronic lymphocytic leukemia. Blood. 2021;138(Supplement 1):640–640.
   Google Scholar
• Roeker LE, Leslie LA, Soumerai JD, et al. A phase 2 study evaluating the addition of ublituximab and umbralisib (U2) to ibrutinib in patients with chronic lymphocytic leukemia (CLL): a minimal residual disease (MRD)-driven, time-limited approach. Blood. 2021;138(Supplement 1):395–395.
   Google Scholar
• Al-Sawaf O, Zhang C, Lu T, et al. Venetoclax-obinutuzumab modulates clonal growth: results of a population-based minimal residual disease model from the randomized CLL14 study. HemaSphere. 2021;5(S2):282.
   Google Scholar
• Jain N, Keating MJ, Thompson PA, et al. Combined ibrutinib and venetoclax for first-line treatment of patients with chronic lymphocytic leukemia (CLL): focus on long-term MRD results. Blood. 2020;136(Supplement 1):42–43.
   Google Scholar
• Thompson PA, Wang Y, Keating MJ, et al. Venetoclax consolidation in patients with high-risk CLL who have been on ibrutinib more than a year achieves a high rate of undetectable minimal residual disease. Blood. 2021;138(Supplement 1):3723–3723.
   Google Scholar
• Barr PM, Hill BT, Ma S, et al. A phase 1/2 study of umbralisib ublituximab and venetoclax in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Blood. 2019;134(Supplement_1):360–360.
   Google Scholar
• Barr PM, Ma S, Zent CS, et al. 1/2 Study of umbralisib, ublituximab, and venetoclax (U2-Ven) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL. American Society of Hematology Annual Meeting & Exposition (Virtual)Abstract Book for the 25th Congress of the European Hematology Association Virtual Edition, 2020, in HemaSphere: June 2020 - Volume 4; 2020 Dec 7–11
   Google Scholar
• Scarfò L, Heltai S, Albi E, et al. Minimal residual disease-driven treatment intensification with sequential addition of ibrutinib (IBR) to venetoclax (VEN) in relapsed/refractory chronic lymphocytic leukemia (CLL): the IMPROVE study. HemaSphere. 2021;5(S2):283–284.
   Google Scholar
• Al-Sawaf O, Zhang C, Robrecht S, et al. Clonal dynamics after venetoclax-obinutuzumab therapy: novel insights from the randomized, phase 3 CLL14 trial. Blood. 2020;136(Supplement 1):22–23.
   Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745–2760.
   PubMed Web of Science ®Google Scholar
• Letestu R, Cartron G, Lepretre S, et al. Minimal residual disease (MRD) by 8-color flow cytometry (Flow-MRD) and IGH clonospecific quantitative PCR (ASO RQPCR) reached similar performances for evaluation of CLL treatment in a phase II clinical trial: cross validation of the methods. Blood. 2014;124(21):3307–3307.
   Web of Science ®Google Scholar
• Rawstron AC, Villamor N, Ritgen M, et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia. 2007;21(5):956–964.
   PubMed Web of Science ®Google Scholar